Factors Affecting Clinical Course and Mortality among COVID-19 Patients Receiving Convalescent Plasma Treatment


  • Ufuk Sonmez Izmir Bozyaka Training and Research Hospital/Infectious Disease and Clinical Microbiology Izmir,Turkey
  • Sabri Atalay Izmir Tepecik Training and Research Hospital /Infectious Disease and Clinical Microbiology Izmir,Turkey
  • Hilal Abakay Izmir Tepecik Training and Research Hospital /Infectious Disease and Clinical Microbiology Izmir,Turkey
  • Derya Çağlayan Dokuz Eylül University/ Epidemiology İzmir/Turkey
  • Alpay Arı Izmir Bozyaka Training and Research Hospital/Infectious Disease and Clinical Microbiology Izmir,Turkey
  • Hüseyin Özkarakaş Izmir Bozyaka Training and Research Hospital/Infectious Disease and Clinical Microbiology Izmir,Turkey
  • Esra Uğur Izmir Tepecik Training and Research Hospital /Infectious Disease and Clinical Microbiology Izmir,Turkey




In this study, our research objectives are; to evaluate death risk covariates and the clinical course of the COVID-19 patients who had received convalescent plasma treatment. This study was performed between April 2020 -April 2021, retrospectively. The study was conducted at two centers in Izmir, Turkey. Demographic characteristics, number of plasma given, the time between the onset of the symptoms and the first plasma treatment, and laboratory results(C-reactive protein, white blood cell, thrombocyte, lymphocyte counts, D-dimer, alanine aminotransferase, aspartate aminotransferase, and procalcitonin) are recorded. Biochemical parameters and the necessity of oxygen support for the patients were evaluated on days 0, 3, and 7 of the first plasma treatment. Death risk covariates were analyzed. Described as moderate, severe, and critical, 199 patients were included in this study. The patients' mean age of the patients was63.7±14.2 (min:24-max:93). Most patients were in the severe group (41.7%). The frequency of necessity of non-invasive mechanical ventilation/mechanical ventilation (NIMV/MV) support on day three and day seven was lower than on day 0 (p:0.004). C-reactive protein and procalcitonin levels were progressively decreased on day three and day 7 (p<0.001, p<0.001).Multivariate analysis showed that; ?65 years of age (HR:1.62 [1.06–2.49]),critical disease severity(HR:2.64 [1.10–6.30]), necessity of corticosteroid treatment (HR:2.22 [1.29–3.82]), leukocyte counts of ?4.23x103/UL (HR:2.10 [1.19–3.69]), lymphocyte levels of ?0.80 x103/UL (HR:1.74 [1.06–2.86]), AST levels of ? 50 U/L (HR:2.18[1.42–3.34]), and procalcitonin levels of  ?0.5 ng/ml (HR:1.91 [1.26–2.91]) on day 3 were found independently associated with mortality. As a result, being older than 65 years old, having acute disease, receiving corticosteroids, having low lymphocyte-leucocyte counts, and having high ALT and procalcitonin levels are associated with mortality. Considering our findings, we think that more studies are needed in the patient groups.


ProMED. Undiagnosed pneumonia–China (Hubei): Request for information. ProMED International Society for Infectious Diseases. 2019 Dec 30.

World Health Organization (WHO). World Health Organization Press Conference The World Health Organization (WHO) Has Officially Named the Disease Caused by the Novel Coronavirus as COVID-19 [Internet]. 2020.

Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, Haagmans BL, Lauber C, Leontovich AM, Neuman BW, Penzar D. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 5, 536–544 (2020). https://doi.org/10.1038/s41564-020-0695-z

Johns Hopkins University of Medicine, Coronavirus Resource Center , COVID-19 Dashboard. https://coronavirus.jhu.edu/map.html (Accessed on April 26,2022).

Wooding DJ, Bach H. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks. Clinical Microbiology and Infection. 2020 Oct 1; 26(10): 1436-46.

Recommendations for Investigational COVID-19 Convalescent Plasma. https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma. (Accessed on June 1, 2020).

COVID-19 i?mmün (konvalesan) plazma tedari?k ve kli?ni?k kullanim rehberi? - 2020. https://shgmkanhizmetleridb.saglik.gov.tr/TR-76536/covid-19-immun-konvalesan-plazma-tedarik-ve-klinik-kullanim-rehberi-guncellendi.html (Accessed on September 13, 2021).

Hegerova L, Gooley TA, Sweerus KA, Maree C, Bailey N, Bailey M, Dunleavy V, Patel K, Alcorn K, Haley R, Johnsen JM, Konkle BA, Lahti AC, Alexander ML, Goldman JD, Lipke A, Lim SJ, Sullivan MD, Pauk JS, Pagel JM. Use of convalescent plasma in hospitalized patients with COVID-19: case series. Blood. 2020 Aug 6; 136(6): 759-762. doi: 10.1182/blood.2020006964. PMID: 32559767; PMCID: PMC7414587.

T.C. Sag?l?k Bakanl?g?? (2020). COVID-19 I?mmu?n (Konvalesan) Plazma Tedarik ve Klinik Kullan?m Rehberi (online). Website: https://shgm.saglik.gov.tr/TR-65033/covid-19-immun-konvale-san-plazma-tedarik-ve-klinik-kullanim-rehberi-yayinlanmistir. html (accessed 16 March 2021).

World Health Organization. Report of the WHO-China joint mission on coronavirus disease 2019 (COVID?19), 16-24 February 2020. https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf. (accessed on 12 August 2022)

Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, Fan Y, Zheng C. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020 Apr; 20(4): 425-434. doi: 10.1016/S1473-3099(20)30086-4. Epub 2020 Feb 24. PMID: 32105637; PMCID: PMC7159053.

Soo YO, Cheng Y, Wong R, Hui DS, Lee CK, Tsang KK, Ng MH, Chan P, Cheng G, Sung JJ. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect. 2004 Jul; 10(7): 676-8. doi: 10.1111/j.1469-0691.2004.00956.x. PMID: 15214887; PMCID: PMC7129386.

Janiaud P, Axfors C, Schmitt AM, Gloy V, Ebrahimi F, Hepprich M, Smith ER, Haber NA, Khanna N, Moher D, Goodman SN, Ioannidis JPA, Hemkens LG. Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis. JAMA. 2021 Mar 23; 325(12): 1185-1195. doi: 10.1001/jama.2021.2747. PMID: 33635310; PMCID: PMC7911095.

Therapeutics and COVID-19. Living guideline. 7 December 2021. https://apps.who.int/iris/bitstream/handle/10665/350177/WHO-2019-nCoV-therapeutics-2021.4-eng.pdf. (accessed 12 August 2022)

Muhammad R, Ogunti R, Ahmad B, Munawar M, Donaldson S, Sumon M, Kibreab A, Thomas AN, Mehari A. Clinical Characteristics and Predictors of Mortality in Minority Patients Hospitalized with COVID-19 Infection. J Racial Ethn Health Disparities. 2022 Feb; 9(1): 335-345. doi: 10.1007/s40615-020-00961-x. Epub 2021 Feb 4. Erratum in: J Racial Ethn Health Disparities. 2022 Jun; 9(3): 1096. PMID: 33538998; PMCID: PMC7861003.

Corona G, Pizzocaro A, Vena W, Rastrelli G, Semeraro F, Isidori AM, Pivonello R, Salonia A, Sforza A, Maggi M. Diabetes is most important cause for mortality in COVID-19 hospitalized patients: Systematic review and meta-analysis. Rev Endocr Metab Disord. 2021 Jun; 22(2): 275-296. doi: 10.1007/s11154-021-09630-8. Epub 2021 Feb 22. PMID: 33616801; PMCID: PMC7899074.

Liu STH, Lin HM, Baine I, Wajnberg A, Gumprecht JP, Rahman F, Rodriguez D, Tandon P, Bassily-Marcus A, Bander J, Sanky C, Dupper A, Zheng A, Nguyen FT, Amanat F, Stadlbauer D, Altman DR, Chen BK, Krammer F, Mendu DR, Firpo-Betancourt A, Levin MA, Bagiella E, Casadevall A, Cordon-Cardo C, Jhang JS, Arinsburg SA, Reich DL, Aberg JA, Bouvier NM. Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study. Nat Med. 2020 Nov; 26(11): 1708-1713. doi: 10.1038/s41591-020-1088-9. Epub 2020 Sep 15. PMID: 32934372.

Kai Duan, Bende Liu, Cesheng Li, Huajun Zhang, Ting Yu, Jieming Qu, Min Zhou, Li Chen, Shengli Meng, Yong Hu, Cheng Peng, Mingchao Yuan, Jinyan Huang, Zejun Wang, Jianhong Yu, Xiaoxiao Gao, Dan Wang, Xiaoqi Yu, Li Li, Jiayou Zhang, Xiao Wu, Bei Li, Yanping Xu, Wei Chen, Yan Peng, Yeqin Hu, Lianzhen Lin, Xuefei Liu, Shihe Huang, Zhijun Zhou, Lianghao Zhang, Yue Wang, Zhi Zhang, Kun Deng, Zhiwu Xia, Qin Gong, Wei Zhang, Xiaobei Zheng, Ying Liu, Huichuan Yang, Dongbo Zhou, Ding Yu, Jifeng Hou, Zhengli Shi, Saijuan Chen, Zhu Chen, Xinxin Zhang, and Xiaoming Yang. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020 Apr 28; 117(17): 9490-9496. doi: 10.1073/pnas.2004168117.




How to Cite

Sonmez, U., Atalay, S., Abakay, H., Çağlayan, D., Arı, A., Özkarakaş, H., & Uğur, E. (2022). Factors Affecting Clinical Course and Mortality among COVID-19 Patients Receiving Convalescent Plasma Treatment. Tropical Health and Medical Research, 5(1). https://doi.org/10.35916/thmr.v4i1.74